Dora Martinez
Family Medicine · Santa Rosa, TXNPI 1811217003
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $198,366 of the $269,593 with a category attached, or 73.6%. Viiv Healthcare Company accounts for 89.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $73,748 and has fallen 100.0% since, to $23 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 566 payments — averaging $476.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$240K
- Gilead$25K
- Janssen Products, LP$3K
- Johnson & Johnson$840
- Theratechnologies Inc.$292
- Napo Pharmaceuticals Inc$81
- plus $235 from 6 others
Across 10 payments — averaging $5201.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$30K
- Gilead$22K
What the payments were for
- Consulting fees$35,68013%
- Speaking & faculty fees$198,36674%
- Travel & lodging$25,73510%
- Food & beverage$9,3633%
- Education$4490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 398 | $240,024 |
| Gilead | 66 | $24,901 |
| Janssen Products, LP | 9 | $3,220 |
| Johnson & Johnson(2 entities) | 69 | $840 |
| Theratechnologies Inc. | 9 | $292 |
| Napo Pharmaceuticals Inc | 3 | $81 |
| EMD Serono, Inc. | 3 | $71 |
| Merck | 3 | $57 |
| Janssen Scientific Affairs, LLC | 2 | $36 |
| Medicines360 | 1 | $30 |
| AbbVie | 2 | $29 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$269,593 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 21 | $80,156 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $60,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $24,901 | $80,15621 claims |
| Viiv Healthcare CompanyDovato | $240,024 | $60,47121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Santa Rosa
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.